Stocktoria

Solventum Corp SOLV

NYSE · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2024-03-26 · LEI

Solventum Corp (SOLV) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $8.3B at a 18.7% net margin.

Chart by TradingView
64/100
Stocktoria Quality Score · grade B
6/9
Piotroski F — financial health
2.34
Altman Z″ — distress risk · grey
Dividend yield · no dividend
-2.06
Beneish M-score — earnings quality · grey

Quality score trend · recomputed for each fiscal year

Piotroski F /9
3 6 20242025
Altman Z″
1.05 2.34 20242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$85.29 as of 2026-08-01 · +16.7% 1y
$65.30$85.4452-wk

Beneish M-score: -2.06 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$13.8B
P / E8.9×
Net margin 5y avg13.6%
Return on equity 5y avg19.5%
Beta0.67
Employees20,584

Analyst price target

$93.92 +10.1% vs last
consensus: buy · 13 analysts
target range $70.00 – $113.00 · median $95.00
1 strong buy · 7 buy · 5 hold · 1 sell · 1 strong sell
Recent analyst actions
DateFirmRating
2026-08-06UBSBuy (main)
2026-08-06Piper SandlerOverweight (main)
2026-08-06WedbushOutperform (main)
2026-08-06KeybancOverweight (main)
2026-08-06StifelBuy (main)
2026-08-06BTIGBuy (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Forward estimates · earnings calendar →

Forward EPS est.$7.22
Forward P / E11.8×

Consensus analyst estimates and scheduled dates — forward-looking, may change.

Revenue trend · last 3y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 78%
Net marginstronger than 92%
Return on equitystronger than 94%
Revenue growthstronger than 36%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · grey zone

ComponentValue
Working capital / assets0.051
Retained earnings / assets0.126
EBIT / assets0.153
Equity / liabilities0.546

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
SOLVSolventum Corp6/92.348.9+0.9%
BAXBAXTER INTERNATIONAL INC5/93.86+5.7%
RMDRESMED INC8/98.6520.7+9.8%
DXCMDEXCOM INC7/94.9832.4+15.6%
MMEDMiniMed Group, Inc.3/94.28+14.3%
WSTWEST PHARMACEUTICAL SERVICES INC7/99.3447.2+6.3%
GMEDGLOBUS MEDICAL INC7/910.0621.8+16.7%

All Manufacturing companies →

About Solventum Corp

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

FAQ

Is SOLV financially healthy?

Solventum Corp's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.

Does SOLV pay a dividend?

No, Solventum Corp does not currently pay a dividend.

How profitable is SOLV?

In FY2025, Solventum Corp had a net margin of 18.7% and a return on equity of 30.8%.

What is SOLV's P/E ratio?

Solventum Corp's trailing price-to-earnings (P/E) ratio is about 8.9×, based on its latest annual earnings.

What is the analyst price target for SOLV?

The average Wall-Street price target for Solventum Corp is $93.92, about 10.1% above the recent price, from 13 analysts (consensus: buy).

Is SOLV a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Solventum Corp: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone, a P/E of about 8.9×. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.